What is the role for donor natural killer cells after nonmyeloablative conditioning?
- PMID: 19361750
- PMCID: PMC2735498
- DOI: 10.1016/j.bbmt.2009.01.018
What is the role for donor natural killer cells after nonmyeloablative conditioning?
Abstract
We investigated the impacts of the tempo of early (days 14, 28, and 42) donor T cell and natural killer (NK) cell engraftment, missing recipient killer cell immunoglobulin-like receptor (KIR) ligands, and numbers of donor inhibitory and activating KIR genes on hematopoietic cell transplantation (HCT) outcomes in 282 patients with hematologic malignancies given nonmyeloablative conditioning. Modeling chimerism levels as a continuous linear variable, we found that high early donor T cell chimerism was significantly associated with acute graft-versus-host disease (aGVHD) (P = .01), whereas high donor NK cell chimerism levels had no such association (P = .38). Conversely, high donor NK cell chimerism levels were significantly associated with low relapse risk (P = .0009), whereas no significant association was seen with high donor T cell chimerism (P = .10). The qualitative associations between donor T cell and NK cell chimerism levels and GVHD and relapse did not change after adjustment for the presence of recipient KIR ligands or numbers of donor inhibitory or activating KIR genes. Our data indicate that prompt engraftment of donor NK cells correlated with lessened risks of relapse, but not with GVHD, whereas the converse was true for T cells.
Figures
Similar articles
-
High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.Leukemia. 2005 May;19(5):822-8. doi: 10.1038/sj.leu.2403718. Leukemia. 2005. PMID: 15772701
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant. 2008 Apr;41(8):709-14. doi: 10.1038/sj.bmt.1705954. Epub 2008 Jan 14. Bone Marrow Transplant. 2008. PMID: 18195688
-
NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.Exp Hematol. 2003 Oct;31(10):911-23. doi: 10.1016/s0301-472x(03)00224-8. Exp Hematol. 2003. PMID: 14550807
-
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.Leukemia. 2006 Oct;20(10):1690-700. doi: 10.1038/sj.leu.2404335. Epub 2006 Jul 27. Leukemia. 2006. PMID: 16871276 Review.
Cited by
-
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.Biol Blood Marrow Transplant. 2013 Sep;19(9):1340-7. doi: 10.1016/j.bbmt.2013.06.002. Epub 2013 Jun 11. Biol Blood Marrow Transplant. 2013. PMID: 23769990 Free PMC article. Clinical Trial.
-
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplant. 2014 Mar;49(3):389-96. doi: 10.1038/bmt.2013.204. Epub 2014 Jan 13. Bone Marrow Transplant. 2014. PMID: 24419525
-
Biology and clinical effects of natural killer cells in allogeneic transplantation.Curr Opin Oncol. 2010 Mar;22(2):130-7. doi: 10.1097/CCO.0b013e328335a559. Curr Opin Oncol. 2010. PMID: 20010294 Free PMC article. Review.
-
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11. J Clin Oncol. 2013. PMID: 23478054 Free PMC article.
-
Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioning.PLoS One. 2013;8(2):e55876. doi: 10.1371/journal.pone.0055876. Epub 2013 Feb 21. PLoS One. 2013. PMID: 23437070 Free PMC article.
References
-
- Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536. - PubMed
-
- Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763. - PubMed
-
- McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400. - PubMed
-
- Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003. - PubMed
-
- Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents (Review) Leukemia. 2006;20:1661–1672. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources